Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 2/20 | 0.38 |
| ▸ | MASP2 | O00187 | 5/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930183 | 0.97 | MEN1 (0.42) | MEN1KMT2ADPP7CTSDBACE1 | |
| SCHEMBL30193508 | 0.91 | MEN1 (0.45) | MEN1KMT2ADPP7CTSDBACE1 | |
| SCHEMBL30311374 | 0.89 | MEN1 (0.44) | MEN1KMT2ADPP7CTSDBACE1 | |
| SCHEMBL29914541 | 0.89 | MEN1 (0.42) | MEN1KMT2ADPP7CTSDBACE1 | |
| SCHEMBL29630487 | 0.89 | KMT2A (0.46) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL30910373 | 0.89 | KMT2A (0.46) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL5970814 | 0.89 | KMT2A (0.49) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL5970810 | 0.89 | KMT2A (0.49) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL21647349 | 0.89 | KMT2A (0.49) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL30496162 | 0.89 | MEN1 (0.42) | MEN1KMT2ADPP7CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | MEN1 1860/4885KMT2A 4034/4885DPP7 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.